Evolus, Inc. (NASDAQ:EOLS - Get Free Report) Director Karah Herdman Parschauer sold 12,888 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the sale, the director now directly owns 32,183 shares in the company, valued at approximately $418,057.17. The trade was a 28.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Evolus Stock Up 1.9 %
Shares of EOLS stock opened at $13.20 on Friday. The firm has a fifty day moving average of $13.10 and a 200-day moving average of $14.00. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12-month low of $9.25 and a 12-month high of $17.82. The company has a market capitalization of $839.35 million, a price-to-earnings ratio of -14.51 and a beta of 1.28.
Analysts Set New Price Targets
A number of equities analysts have commented on EOLS shares. HC Wainwright restated a "buy" rating and issued a $27.00 price target on shares of Evolus in a research report on Wednesday, March 5th. Barclays upped their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, March 5th.
View Our Latest Analysis on EOLS
Institutional Trading of Evolus
A number of large investors have recently added to or reduced their stakes in EOLS. Tri Locum Partners LP acquired a new stake in Evolus in the fourth quarter valued at $8,198,000. Gilder Gagnon Howe & Co. LLC lifted its stake in shares of Evolus by 287.2% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company's stock worth $7,753,000 after buying an additional 520,859 shares during the last quarter. Caligan Partners LP lifted its stake in shares of Evolus by 22.7% during the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock worth $29,724,000 after buying an additional 498,900 shares during the last quarter. Allostery Investments LP acquired a new stake in shares of Evolus during the 4th quarter worth about $4,760,000. Finally, Altium Capital Management LLC lifted its stake in shares of Evolus by 93.0% during the 4th quarter. Altium Capital Management LLC now owns 685,000 shares of the company's stock worth $7,562,000 after buying an additional 330,000 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.
Evolus Company Profile
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
